aurobindo pharma (GoldmanSachs) FDA seeks action plan for Unit III improvement, maintain Neutral

Date Rating Target Price Recommendation Price Broker house
24 May 2011 neutral 213 175 GoldmanSachs Report

No comments:

Post a Comment